Fig. 4: JWA negatively regulates CDK12.
From: JWA suppresses proliferation in trastuzumab-resistant breast cancer by downregulating CDK12
A Some genes altered significantly after overexpression of JWA by RNA-seq. B The results of KEGG-pathway enrichment analysis showing the cell cycle pathway had the greatest significance. C Somatic genetic alterations identified in 16 trastuzumab-resistant breast cancer patients subjected to NGS. D The intersection frequencies of genetic changes and NGS were ranked top 4 in the order of TP53, PIK3CA, CDK12, PTK2. E The IHC of 12 breast cancer patients through The Human Protein Atlas database, and CDK12 was highly expressed in eight patients and that was moderately expressed in four patients; (×40). F Survival curves showing a comparison of survival rates in patients with HER2+ breast cancer with low and high CDK12 expression. G Scatter plot showing the correlation between JWA and CDK12 expression in the breast cancer microarray data GSE19615. MUT mutation; AMP amplification.
